To evaluate the impact of long-term Avn-C treatment initiated at the early AD stage on microglial activation and morphology, we measured the area of the microglial cell body (soma), marked by Iba1, in the CA3 region of the hippocampus in Tg2576 mice. Here, AIF1 is linked to Alzheimer disease.